Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)

NCT00638963 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated due to poor accrual

Conditions

Breast Neoplasm
Brain Neoplasm
Second Neoplasm

Interventions

DRUG: temozolomide

Sponsor

Merck Sharp & Dohme LLC